MSU
ASBP

Mizuho Securities USA’s Aspire Biopharma ASBP Stock Holding History

Mizuho Securities USA’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29
Closed -$376K – 214
2023
Q3 		$376K Buy
+29
New +$374K 0.01% 181

Other funds holding ASBP

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Mizuho Securities USA's ASBP Position: Q4 2023 in Review

Mizuho Securities USA sold out of Aspire Biopharma (ASBP) in Q4 2023, closing a stake of 29 shares — an estimated $376K sold.

Mizuho Securities USA first reported a position in ASBP in Q3 2023 and held it in 1 quarter. The position peaked at $376K in Q3 2023. 19 funds tracked by Wall St. Rank hold ASBP as of Q4 2023.

  • Mizuho Securities USA reported no remaining Aspire Biopharma position as of Q4 2023 after selling out during the quarter.
  • Mizuho Securities USA sold 29 Aspire Biopharma shares in Q4 2023, an estimated $376K.
  • Mizuho Securities USA first reported a position in Aspire Biopharma in Q3 2023 and held it in 1 quarter.
  • Mizuho Securities USA's Aspire Biopharma position peaked at $376K in Q3 2023.
  • 19 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2023.

Based on Mizuho Securities USA's 13F filing for Q4 2023, filed 8 Feb 2024.